Biotech start-ups may soon be able to travel a repaved Regulation A route to raise up to $50 million.
LONDON – It may soon be possible to develop new analgesics that are as good as morphine when it comes to killing pain, yet do not have any of the unpleasant and sometimes dangerous side effects of that drug, such as constipation and respiratory depression. Researchers in France said they believe such ideal painkillers are within reach. more »
Shopping among European collaborators for its drug-device pain combo known as Zalviso, Acelrx Pharmaceuticals Inc. “had a number of different suitors approach us,” with “a lot of very large-scale players interested,” said CEO Richard King. more »
- Anoro Ellipta set to take on U.S. chronic obstructive pulmonary disease market
- HCV regimen wins in Phase III; Street’s ‘ION’ Gilead pricing
- Onconova’s pancreatic bid fizzles; rigosertib still alive in MDS
- SEC proposes rule to make Regulation A a viable route
- Depomed snaps up Nautilus migraine drug for $48.7M
- Chengdu Kanghong wins CFDA nod as China’s first novel MAb
- China’s blood product makers face potentially challenging year
- Advaxis kicks off global strategy in licensing deal with Taiwanese start-up
- Late or just in time – a U.S. big biotech arrives, ready to innovate
- For South Korean firms, biosimilars are gateway ...
There is no doubt that Canada is a global leader when it comes to biotech innovation. However, it’s no secret that the country has been challenged in its ability to successfully translate promising medical discoveries made at its universities and research institutions into viable commercial projects capable of attracting venture capital and industry interest.
Researchers have gained new insights into the autoimmune roots of narcolepsy – findings that will allow both easier diagnosis of the disorder, and “a model to understand other autoimmune disorders,” Stanford University’s Emmanuel Mignot told BioWorld Today.
- Molecular underpinnings of cancers on the move »
- More specific targeting opens door to wider car T-cell use »
- Study starts to tease out low-frequency cancer-causing mutations »
- Adaptimmune ‘besieged’ with suitors following its MM data report »
- Kinder, gentler treatments for older, sicker patients »
- Stem cell advance offers prospect of cure for genetic liver diseases »
- CLL combos coming, melanoma semblances only skin deep »
- Caged Toxin Makes for a Better Vaccine »
- Histone Deacetylases Can Work Without Deacetylating Histones »
Suite: 1100 | Atlanta, Georgia 30346, USA
In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-770-810-3144
In the U.S. and Canada: 1-800-336-4474
Outside the U.S.: 1-215-386-0100
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Sign up for Perspectives FREE e-mail newsletter